Drug combo before & after surgery for HER2+ stomach cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of three drugs (targeted therapy, immunotherapy, and chemotherapy) before and after surgery for locally advanced HER2-positive stomach cancer. It aims to see if this treatment can improve outcomes for patients whose cancer has not yet spread.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- Your cancer is stage II or III (has not spread to other organs).
- Your tumor has high levels of HER2 protein (HER2-positive).
- You have not had any previous treatment for this cancer.
- You are in generally good health (ECOG 0-1) and your organs work normally.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (Disitamab Vedotin, Toripalimab, and XELOX) given before and after surgery for gastric or gastroesophageal junction cancer. The goal is to see if this treatment helps shrink the tumor and prevent it from coming back.
This trial tests a new combination of drugs (RC48, sintilimab, and SOX chemotherapy) for people with stomach or gastroesophageal junction cancer that cannot be removed by surgery, has not been treated before, and has a specific HER2 score (1+ or 2+). The goal is to shrink the tumor enough to possibly allow surgical removal.
This trial tests a new approach for stomach cancer that has spread to nearby tissues but not to other organs. You would get a short course of radiation, followed by a combination of targeted therapy (Disitamab Vedotin), chemotherapy (S-1), and immunotherapy (Sintilimab) before surgery to shrink the tumor and improve outcomes.
This trial tests a new immunotherapy called rilvegostomig combined with standard chemotherapy and a targeted therapy (trastuzumab deruxtecan) for people with advanced HER2-positive stomach or gastroesophageal junction cancer that has not been treated before.
This trial is testing a new combination of drugs (targeted therapy plus immunotherapy plus chemotherapy) for people with a specific type of advanced stomach cancer called HER2-low. The goal is to see if this combination works better than the current standard immunotherapy plus chemotherapy.
This trial tests a new combination of drugs (Disitamab Vedotin, Trastuzumab, and Tislelizumab) against standard chemotherapy plus Trastuzumab (with or without Pembrolizumab) for people with advanced or metastatic stomach or gastroesophageal junction cancer that has high levels of HER2. The goal is to see if the new combination works better.
Hear when a new Gastric Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.